摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-carbethoxy-5-aminoacetyl-10,11-dihydro-5H-dibenzazepine | 132900-42-6

中文名称
——
中文别名
——
英文名称
3-carbethoxy-5-aminoacetyl-10,11-dihydro-5H-dibenzazepine
英文别名
ethyl (5-glycyl-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)carbamate;3-carbethoxyamino-5-amino-acetyl-10,11-dihydro-5H-dibenz[b,f]azepine;Carbamic acid, (5-(aminoacetyl)-10,11-dihydro-5H-dibenz(b,f)azepin-3-yl)-, ethyl ester;ethyl N-[11-(2-aminoacetyl)-5,6-dihydrobenzo[b][1]benzazepin-2-yl]carbamate
3-carbethoxy-5-aminoacetyl-10,11-dihydro-5H-dibenz<b,f>azepine化学式
CAS
132900-42-6
化学式
C19H21N3O3
mdl
——
分子量
339.394
InChiKey
HJGLLZCKMKRCLO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    158-159 °C
  • 沸点:
    532.8±50.0 °C(Predicted)
  • 密度:
    1.277±0.06 g/cm3(Predicted)
  • 溶解度:
    36.6 [ug/mL]

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    84.7
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:95b992d5d7b02bd03602bd25d5a8c7ba
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    马来酸酐3-carbethoxy-5-aminoacetyl-10,11-dihydro-5H-dibenzazepine溶剂黄146 作用下, 反应 12.0h, 以6.29%的产率得到ethyl (5-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)carbamate
    参考文献:
    名称:
    [EN] SELECTIVE INHIBITORS OF CONSTITUTIVE ANDROSTANE RECEPTOR
    [FR] INHIBITEURS SÉLECTIFS DU RÉCEPTEUR CONSTITUTIF DES ANDROSTANES
    摘要:
    本发明的化合物是CAR的拮抗剂,对CAR的特异性高于其他蛋白,包括PXR。所披露的化合物可用于治疗或控制细胞增殖障碍,特别是肿瘤学疾病,例如癌症。本摘要旨在作为特定技术领域搜索的扫描工具,并不是要限制本发明。
    公开号:
    WO2016064682A1
  • 作为产物:
    描述:
    亚氨基二苄盐酸甲醇ammonium hydroxide硫酸 、 palladium on activated charcoal 、 氢气硝酸 、 sodium carbonate 、 溶剂黄146 作用下, 以 甲醇乙醇甲苯 为溶剂, 反应 19.5h, 生成 3-carbethoxy-5-aminoacetyl-10,11-dihydro-5H-dibenzazepine
    参考文献:
    名称:
    [EN] SELECTIVE INHIBITORS OF CONSTITUTIVE ANDROSTANE RECEPTOR
    [FR] INHIBITEURS SÉLECTIFS DU RÉCEPTEUR CONSTITUTIF DES ANDROSTANES
    摘要:
    本发明的化合物是CAR的拮抗剂,对CAR的特异性高于其他蛋白,包括PXR。所披露的化合物可用于治疗或控制细胞增殖障碍,特别是肿瘤学疾病,例如癌症。本摘要旨在作为特定技术领域搜索的扫描工具,并不是要限制本发明。
    公开号:
    WO2016064682A1
点击查看最新优质反应信息

文献信息

  • Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor
    作者:Wenwei Lin、Lei Yang、Sergio C. Chai、Yan Lu、Taosheng Chen
    DOI:10.1016/j.ejmech.2015.12.018
    日期:2016.1
    Constitutive androstane receptor (CAR, NR1I3) and pregnane X receptor (PXR, NR1I2) are master regulators of endobiotic and xenobiotic metabolism and disposition. Because CAR is constitutively active in certain cellular contexts, inhibiting CAR might reduce drug-induced hepatotoxicity and resensitize drug resistant cancer cells to chemotherapeutic drugs. We recently reported a novel CAR inhibitor/inverse agonist CINPA1 (11). Here, we have obtained or designed 54 analogs of CINPA1 and used a time-resolved fluorescence resonance energy transfer (TR-FRET) assay to evaluate their CAR inhibition potency. Many of the 54 analogs showed CAR inverse agonistic activities higher than those of CINPA1, which has an IC50 value of 687 nM. Among them, 72 has an IC50 value of 11.7 nM, which is about 59-fold more potent than CINPA1 and over 10-fold more potent than clotrimazole (an IC50 value of 126.9 nM), the most potent CAR inverse agonist in a biochemical assay previously reported by others. Docking studies provide a molecular explanation of the structure activity relationship (SAR) observed experimentally. To our knowledge, this effort is the first chemistry endeavor in designing and identifying potent CAR inverse agonists based on a novel chemical scaffold, leading to 72 as the most potent CAR inverse agonist so far. The 54 chemicals presented are novel and unique tools for characterizing CAR's function, and the SAR information gained from these 54 analogs could guide future efforts to develop improved CAR inverse agonists. (C) 2015 Elsevier Masson SAS. All rights reserved.
  • Synthesis of a new antiarrhythmic agent — Bonnecor
    作者:A. P. Skoldinov、A. N. Gritsenko、H. Wunderlich、A. Stark、E. Carstens、D. Loman
    DOI:10.1007/bf00766590
    日期:1990.12
  • 3-Alkoxycarbonylamino-5-acylaminoiminodibenzyls and their antiarrhythmic activity
    作者:A. P. Skoldinov、N. V. Kaverina、A. N. Gritsenko、V. V. Lyskovtsev、A. I. Turilova、H. Wunderlich、A. Stark、H. Poppe、R. Barch、L. Zenker、D. Loman
    DOI:10.1007/bf02219697
    日期:1996.3
  • SKOLDINOV, A. P.;GRITSENKO, A. N.;VUNDERLIX, X.;SHTARK, A.;KARSTENS, E.;L+, XIM.-FARMATS. ZH., 24,(1990) N2, S. 51-53
    作者:SKOLDINOV, A. P.、GRITSENKO, A. N.、VUNDERLIX, X.、SHTARK, A.、KARSTENS, E.、L+
    DOI:——
    日期:——
  • SELECTIVE INHIBITORS OF CONSTITUTIVE ANDROSTANE RECEPTOR
    申请人:ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    公开号:US20170226115A1
    公开(公告)日:2017-08-10
    The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
查看更多